|
|
 Previous Article | Table of Contents | Next Article 
A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting
both t (14;18) and t(4;11) chromosomal translocations
MJ Dyer, P Fischer, E Nacheva, W Labastide and A Karpas
Department of Haematology, University of Cambridge, UK.
A unique B-cell non-Hodgkin's lymphoma (NHL) cell line (Karpas 422),
bearing both t(14;18) and t(4;11) chromosomal translocations as well as
several other chromosomal abnormalities, has been established from the
pleural effusion of a patient with chemotherapy-resistant NHL. This cell
line has the same karyotypic features as malignant cells from the patient.
The major cell clone is characterized chromosomally by 46,XX
t(2;10)(p23;q22.1), t(4;11)(q21.3; q23.1), t(14;18)(q32.1;q21.3),
t(4;16)(q21.3;p13.1). Both phenotypically and genotypically, the cell line
has features of a mature B-cell neoplasm with no evidence for commitment to
other lineages. Rearrangements of the C-ETS-1 oncogene and N-CAM-1 and CD3
genes that map to 11q23 were not detected by conventional Southern
analysis. BCL-2 was rearranged within the major breakpoint cluster. The
K422 cell line has a unique karyotype; this is the first occasion that the
t(4;11) translocation has been described in a t(14;18) lymphoma. The cell
line will be of value in determining the molecular nature of the t(4;11)
translocation.
Volume 75,
Issue 3,
pp. 709-714,
02/01/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Song, A. Zlobin, P. Ghoshal, Q. Zhang, C. Houde, S. Weijzen, Q. Jiang, E. Nacheva, D. Yagan, E. Davis, et al.
Alteration of SMRT Tumor Suppressor Function in Transformed Non-Hodgkin Lymphomas
Cancer Res.,
June 1, 2005;
65(11):
4554 - 4561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ghielmini, S.-F. H. Schmitz, S. B. Cogliatti, G. Pichert, J. Hummerjohann, U. Waltzer, M. F. Fey, D. C. Betticher, G. Martinelli, F. Peccatori, et al.
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
Blood,
June 15, 2004;
103(12):
4416 - 4423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ota, H. Tagawa, S. Karnan, S. Tsuzuki, A. Karpas, S. Kira, Y. Yoshida, and M. Seto
Identification and Characterization of a Novel Gene, C13orf25, as a Target for 13q31-q32 Amplification in Malignant Lymphoma
Cancer Res.,
May 1, 2004;
64(9):
3087 - 3095.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bevilacqua, M. C. Ceriani, G. Canti, L. Asnaghi, R. Gherzi, G. Brewer, L. Papucci, N. Schiavone, S. Capaccioli, and A. Nicolin
Bcl-2 Protein Is Required for the Adenine/Uridine-rich Element (ARE)-dependent Degradation of Its Own Messenger
J. Biol. Chem.,
June 20, 2003;
278(26):
23451 - 23459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Robetorye, S. D. Bohling, J. W. Morgan, G. C. Fillmore, M. S. Lim, and K. S. J. Elenitoba-Johnson
Microarray Analysis of B-Cell Lymphoma Cell Lines with the t(14;18)
J. Mol. Diagn.,
August 1, 2002;
4(3):
123 - 136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mathas, A. Rickers, K. Bommert, B. Dörken, and M. Y. Mapara
Anti-CD20- and B-cell Receptor-mediated Apoptosis: Evidence for Shared Intracellular Signaling Pathways
Cancer Res.,
December 1, 2000;
60(24):
7170 - 7176.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. Siebert, S. Gesk, S. Harder, S. Plotz, P. Matthiesen, W. Grote, B. Schlegelberger, B. Jandrig, U.-H. Grasmo-Wendler, S. Scherneck, et al.
Deletions in the Long Arm of Chromosome 10 in Lymphomas With t(14;18): A Pathogenetic Role of the Tumor Suppressor Genes PTEN/MMAC1 and MXI1?
Blood,
December 1, 1998;
92(11):
4487 - 4489.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Morelli, D. Delia, S. Capaccioli, A. Quattrone, N. Schiavone, A. Bevilacqua, S. Tomasini, and A. Nicolin
The antisense bcl-2-IgH transcript is an optimal target for synthetic oligonucleotides
PNAS,
July 22, 1997;
94(15):
8150 - 8155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Paulus, P. Dreger, K. Viehmann, N. v. Neuhoff, and N. Schmitz
Purging Peripheral Blood Progenitor Cell Grafts from Lymphoma Cells: Quantitative Comparison of Immunomagnetic CD34+ Selection Systems
Stem Cells,
July 1, 1997;
15(4):
297 - 304.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. T. Voso, S. Hohaus, M. Moos, and R. Haas
Lack of t(14; 18) Polymerase Chain Reaction-Positive Cells in Highly Purified CD34+ Cells and Their CD19 Subsets in Patients With Follicular Lymphoma
Blood,
May 15, 1997;
89(10):
3763 - 3768.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
